TranScrip Partners is coming to America, as the U.K.-based CRO is opening its first stateside office to expand its global footprint.
The company has long offered its drug development services in the EU and expanded to Australia in September. Now, with a foothold in Philadelphia, TranScrip can pitch its end-to-end CRO platform to a larger client base, Managing Partner Flic Gabbay said.
"Establishing TranScrip's presence in the U.S. will allow us to better support our clients and their global drug development programs and will add to the depth and breadth of our expertise in drug development and commercialization," Gabbay said in a statement.
TranScrip bills itself as a one-stop option for outsourcers, handling drug development, medical affairs, pharmacovigilance, regulatory and medical writing for pre- and post-approval. The company has thus far partnered with more than 80 companies across four continents, and, with a U.S. base of operations, TranScrip expects more growth in the future.
- read the announcement